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King Sau
osting by EAbstract A validated method using capillary electrophoresis was developed, for the determination
of orphenadrine citrate in its tablet formulations, in the presence of paracetamol. The method
employs a running buffer of 30 mM pentane sulfonate sodium, dissolved in 20 mM MOPS buffer
pH 7.7. Samples were injected using hydrodynamic sample injection mode (25 mbar, for 25 s), using
positive polarity of 25 kV, at a constant temperature of 30 C. Samples of orphenadrine citrate
alone or in mixture solutions with paracetamol were exposed to various degradation conditions,
and were electrophoresed using the recommended condition. The method was found to be speciﬁc,
linear (r2 = 0.994), precise, accurate, and robust, with an LOQ of 0.02 mg/mL. The proposed
method was successfully applied for measurement of the percentage per label of orphenadrine cit-
rate in commercially available tablets.
ª 2010 King Saud University. All rights reserved.1. Introduction
Orphenadrine citrate (OC) is an analogue of the antihistamine
diphenhydramine (Fig. 1). OC is used as a centrally acting
skeletal muscle relaxant, with some independent analgesic ef-
fects that may contribute to its efﬁcacy in relieving painful(I.I. Hamdan).
ity. All rights reserved. Peer-
d University.
lsevierskeletal muscle spasms (Waldman, 1994; Rumore and Schlich-
ting, 1986; Wallace, 2004). The citrate salt of orphenadrine is
mostly used in combination with paracetamol (PCTM). The
combination between OC and paracetamol has shown superior
analgesic effects, compared to each ingredient when used alone
(Wallace, 2004; Mok et al., 1979; McGuinness, 1983).
Several methods for analysis of OC alone or in combination
with PCTM have been reported. These include spectrophoto-
metric methods (Saleh et al., 2007; Shama, 2002; Ahmad
et al., 2005; Sharaf El-Din et al., 1991), High pressure liquid
chromatography (HPLC) and gas chromatography GC meth-
ods. The reported HPLC methods employed mostly reversed-
phase columns with ultraviolet (UV) or mass spectrometric
(MS) detectors Selkirk et al., 1984; Arayne et al., 2009; Lee
et al., 2006. Using MS/MS as a detector with HPLC, OC
has been analyzed in human plasma, with an overall run time
Figure 1 Structure of orphenadrine citrate.
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versed-phase HPLC method for the simultaneous determina-
tion of OC and PCTM in tablet as well as in plasma, with
an overall run time of 6 min (Arayne et al., 2009).
Gas chromatographic methods have been developed for the
quantitative determination of orphenadrine in human serum,
plasma, and urine (Labout et al., 1977; Lutz et al., 1983; Con-
tin et al., 1988; Bilzer and Gundert-Remy, 1973). The related
substances test for orphinadrine citrated in British pharmaco-
poeia, 2007 (Righetti, 1996) also relies on GC. This method is
capable of separating and determining OC as well as other re-
lated substances including degradation and synthetic impuri-
ties (impurities A to F in the monograph) (Righetti, 1996).
Thin layer chromatography was also used for the quantita-
tive determination of OC and PCTM in tablet formulations
(Sheikh Salem et al., 1989).
A possible explanation for that (using HPLC) could be the
fact that OC is rather a hydrophilic drug with little afﬁnity on
reversed-phase columns. This explanation is supported by the
observation that the only report in which OC had reasonable
retention was that of Selkirk et al. (1984). However, in that re-
port the authors employed sodium dodecyl sulfate to act as an
ion-pairing agent and consequently larger retention for OC.
Therefore, the objective of this study was to develop, optimize,
and validate a capillary electrophoresis-based method for the
analysis of OC in its combined tablet dosage form (with
PCTM) according to the ICH guidelines.
2. Materials and methods
2.1. Materials
Orphenadrine citrate working standard (100% pure) was a gift
from Dar Al Dawa (Nau’r-Jordan). PCTM was obtained from
Acros organics (New Jersey, USA). Boric acid was from Sig-
ma–aldrich (Japan). Glycine was from E. Merck (Darmstadt,
Germany). Analytical grade disodium hydrogen orthophos-
phate was from Gainland Chemical company (UK). Citric acid
anhydrous was from Panreac Quimica (Spain). MOPS (4-mor-
pholino propanesulfonic acid) was from Duchefa (Nether-
lands). Acetonitrile and methanol were obtained from
TEDIA (Inc., USA). Pseudoephedrine (99.6%) and pentane
sulfonate (analytical grade) were a gift from JOSWI Pharma-
ceuticals (Jordan). Sodium dodecyl sulfate was obtained from
Fluka Chemie (Buchs, Switzerland). Norgesic tablets (3 M
Pharmaceuticals, Pty Ltd., Australia, Lot No. T812A) and
Myogesic tablets (Dar Al Dawa, Nau’r-Jordan, Lot No.
010E) were obtained from the local pharmacy shops. Agilent
Technologies capillary electrophoresis system (Germany) with
chemstation software (Rev.A.09.03[1417]) equipped with PDA
detector was used for all measurements.2.2. Methodology
2.2.1. Capillary electrophoresis conditions
The ﬁnally recommended condition was 30 mM (PSNa) dis-
solved in 20 mMMOPS buffer at pH 7.7 with a hydrodynamic
sample injection mode (25 mbar, for 25 s). Throughout the run
the voltage was maintained at 25 kV, at a constant tempera-
ture of 30 C. Pseudoephedrine (0.6 mg/mL) was employed
as the internal standard (I.St).
2.2.2. Preparation of standards
Two standard solutions of OC (0.4 mg/mL and 2 mg/mL) were
prepared in 50% MeOH. A standard solution of PCTM was
prepared to contain 5.14 mg/mL PCTM in 50% MeOH. Sev-
eral buffer solutions were prepared in the course of method
development, including: citrate (20 mM pH 5.2), MOPS
(80 mM, pH 7.7), borate (20 mM, pH 8.8), borate (60 mM,
pH 9.7), glycine (20 mM, pH 10), and phosphate (60 mM,
pH 12). Acetonitrile (ACN) was incorporated as an organic
modiﬁer at different concentrations (5%, 10%, 15%, 20%,
and 30%) in buffer solutions containing 20 mM MOPS at of
pH 7.7.
2.2.3. Buffer additives
Sodium dodecyl sulfate (SDS) was incorporated (at concentra-
tions between 20 and 80 mM) into MOPS, borate, and phos-
phate buffer solutions (each at 20 mM) with pH values 6.7–
12 as appropriate. Generally, buffer solutions were prepared
by transferring 33.3 mL of the appropriate stock buffer solu-
tion (60 mM), into 100 mL ﬂask, mixed with 15 mL ACN,
and volume completed properly up to 100 mL. The so ob-
tained solutions were used to dissolve appropriate weights of
SDS in 25 mL volumetric ﬂasks, to obtain the appropriate con-
centrations of SDS in the corresponding buffer.
Pentane sulfonate sodium (PSNa) was incorporated
(30 mM) in the running buffer (20 mM MOPS buffer, pH
7.7) with or without 30% ACN. Appropriate amounts of
SDS were dissolved in phosphate buffer (20 mM, pH 12) to
obtain buffer solutions containing concentration 0 mM,
5 mM, 10 mM, and 20 mM of SDS, respectively.
2.2.4. Method validation
The peak purity was assessed with the aid of photodiode array
detector. Peak purity was also assessed for solutions prepared
from two commercially available products: Norgesic tablets,
and Myogesic tablets.
For assessment of linearity, a stock solution (6 mg/mL) of
the internal standard (pseudoephedrine) was prepared by dis-
solving 300 mg in 50 mL of 50% MeOH. In each of eight sep-
arate volumetric ﬂasks (10 mL), 1 mL of pseudoephedrine
solution, along with the required volume of OC solution
(2 mg/mL) was transferred, and volume completed properly
with 50% MeOH. Thus eight solutions containing OC in the
range 0.2–0.6 mg/mL were prepared. Each solution prepared
was injected (ﬁve times) using the proposed CE condition.
Sample of 100% test concentration (0.4 mg/mL) was injected
six times. Calibration curves were constructed by plotting peak
area of OC/peak area of pseudoephedrine versus concentration
of OC.
Repeatability was assessed by computing the relative stan-
dard deviation (RSD) for six replicate samples at 100% test
concentration. To assess intermediate precision, six injections
Development of a capillary electrophoresis method for the determination of orphenadrine citrate 235of 100% test concentration were made at two different days.
The RSD of relative responses was computed for each six
injections and for the whole 12 injections.
To assess robustness of the proposed method, six replicate
injections of 100% test concentration were made at conditions
that differ slightly from original condition. Conditions that
slightly differ in buffer pH (±0.2 pH units), or those that
slightly differ in buffer concentration (±2 mM) were examined.
T-test was used to compare mean relative responses (response
of analyte/response of I.St) obtained from the original condi-
tion, and those obtained from the slightly deviating conditions.
2.2.5. Application to commercial tablets
Two commercial tablets were assayed: Norgesic tablets
(batch no. T812A), and Myogesic tablets (batch no. 010E).
Ten tablets were weighed, crushed into powder, and the aver-
age weight for two tablets was measured and (1.38332 g for
Norgesic tablets, and 1.1442 g for Myogesic tablets) was
transferred into a 100 mL volumetric ﬂask, completed up to
volume with 50% MeOH, placed on the sonicator for 15
min, and ﬁltered through 0.45 lm membrane ﬁlter (tablet stock
solution). Proper dilutions of this solution were made to obtain
theoretical concentrations of OC 0.4 mg/mL and 0.6 mg/mL of
the I.St. Three samples were prepared and each sample solu-
tion was injected three times at the proposed CE condition.
3. Results and discussion
3.1. Method development
Capillary electrophoresis method development started with
running buffers at 20 mM level but with different pH values
ranging between 5.2 and 12. The rest of CE conditions were:
66 cm long capillary, a voltage of 25 kV, and a temperature
of 30 C. The obtained migration times for OC (Fig. 2) gener-
ally decreased with increasing pH, except at pH 12. This effect
could be explained in terms of the increase in EOF attained
upon increasing pH, due to increased dissociation of silanol
groups at the internal surface of the capillary. However, the
slight increase in migration time was observed as the pH chan-
ged from 8 to 12 which is most likely attributed to the decrease
in the dissociation of the basic OC. Since the pKa for OC is
around 8.4 (Phar, 1980), then the change in pH in the range
(8–12) would have a signiﬁcant impact on the percentage ofFigure 2 Plot of the migration time of OC and PCTM against
pH of the buffer in the range 5.2–12 (all buffers at 20 mM).the dissociated compound and consequently on its migration
time.
Paracetamol, on the other hand, exhibited longer migration
times compared to OC (Fig. 2) with peak broadening at high
pH values. This agrees with the fact that PCTM is a phenolic
acid with pKa value of 9.5 which makes PCTM almost neu-
tral at pH values less than 9, while OC is positively charged,
thus travels faster towards the detector (cathode). At pH val-
ues of 9.7, PCTM is expected to exist as a mixture of negatively
ionized and non-ionized species which accords with the obser-
vation that PCTM peak became broader as the pH was in-
creased above 8.
Overall, MOPS buffer at pH 7.7 was chosen as the opti-
mum among the ones examined, in terms of peak shape, run
time, and potential separation of the two compounds (OC
and PCTM).
Only minor effect of buffer concentration on migration
time was observed when MOPS buffer at concentrations of
20 mM, 40 mM, 60 mM, and 80 mM were examined. How-
ever, obvious advantage regarding peak sharpness and re-
sponse was obtained at MOPS concentration of 20 mM.
Therefore, 20 mM of MOPS was chosen as the optimum buffer
concentration. Mixture solution containing both OC and
PCTM was injected at different wavelengths (195 nm,
200 nm, 210 nm, 220 nm, 230 nm, 240 nm, and 258 nm) using
a running buffer of 20 mM MOPS buffer pH 7.7. Highest re-
sponse was observed at 195 nm for both compounds, thus it
was taken as the optimum wavelength for monitoring
electropherograms.
In an attempt to further improve peak shape for both ana-
lytes, the effect of ACN as an organic modiﬁer was examined.
Organic modiﬁers affect buffer viscosity, and most of the time
cause a reduction of zeta potential, however, their contribution
to the separation process is complex, and is most easily deter-
mined experimentally (Moffatet al., 1986). Mixture solution of
OC and PCTM was injected using MOPS buffer (20 mM, pH
7.7) containing ACN at different levels (5%, 10%, 15%, 20%,
and 30%). Generally, the effect of ACN (5–30%) was found
not to be dramatic. Based on sharpness of peaks, the optimum
concentration of ACN was taken as 15%.
To evaluate the effect of sample solvent on the electropho-
retic behavior of analytes, mixture solutions of OC and PCTM
prepared in 50% MeOH, D.W, or the employed background
electrolyte were injected using MOPS buffer (20 mM, pH
7.7) containing 15% ACN. Among the three sample solvents
tested, the best one (in terms of sharpness of peaks and base-
line) was MeOH 50%.
In attempts to further improve efﬁciency of electrophoresis
(peak shape); PSNa was incorporated inMOPS buffer (20 mM,
pH 7.7) containing 0% or 30% ACN. Signiﬁcant improve-
ments in peak shape and migration times were obtained,
though the condition was found not capable of separating
PCTM from buffer-related peaks (Fig. 3). Nevertheless, this
was considered as the optimum condition for determination
of OC in the presence of PCTM as high efﬁciency for OC peak
was achieved. Thus the ﬁnally recommended conditions were:
30 mM PSNa, dissolved in 20 mM MOPS buffer pH 7.7.
3.2. Method validation
According to ICH guidelines, the linearity of the method
should be established in the range of 80–120% of the expected
Figure 3 Electropherograms for (A) OC solution 1 (B) Mixture solution (0.4 mg/mL OC, and 5.14 mg/mL PCTM), exposed to sunlight
(30 days). Running buffer: 30 mM PSNa, dissolved in 20 mM MOPS buffer pH 7.7.
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linear with a correlation coefﬁcient of 0.994 (n= 5). Since the
proposed method proved to be linear, selective, and precise
within this range (80–120%), it could be concluded that the
range for the proposed method is between 0.32 mg/mL and
0.48 mg/mL.
Repeatability was assessed by computing the relative stan-
dard deviation (RSD) for six replicate samples at 100% test
concentration. A typical RSD value of 0.42 was obtained,
which essentially indicates good precision. To assess intermedi-
ate precision, six injections of 100% test concentration were
made at two different days. The RSD of relative responses
was computed, for each six injections and for the whole 12
injections. The obtained RSD values were 0.42, 0.81, and
1.27 for the ﬁrst day, second day, and the two days together,
respectively. All RSD values were satisfactory indicating
acceptable intermediate precision.
According to ICH guidelines, accuracy could be deter-
mined by subjecting a tablet (made with known amount
of the analyte) to analysis, and comparing the results to
theoretical values. Because the placebo (tablet additives)
was not known or available, a second approach that was
allowed by the ICH in such cases was adopted. That is
to infer accuracy from speciﬁcity, linearity, and precision.
Accordingly, the proposed method could be concluded
accurate, because speciﬁcity, linearity, and precision were
proven.
The robustness of the method was assessed by changing the
pH ±0.2 units, and the concentration of the buffer ±2 mM
from the recommended condition. Electropherograms were
obtained for a standard solution of OC at 100% test concen-
tration (n= 6). T-test was used to compare the results ob-
tained at each of the deviated conditions (±0.2 pH units,
and ±2 units of mM) to those obtained using the recom-
mended condition. When the pH was 7.5 instead of 7.7 or buf-
fer concentration was 18 instead of 20 mM, the results were
statistically different from those at the recommended condi-
tion. At pH values of 7.9 or buffer concentrations of 22 mM
the obtained results were not signiﬁcantly different from those
obtained at the recommended conditions. However, it has to
be stressed that it is usually not difﬁcult to ensure buffer con-
centration with much better accuracy than ±2 mM, and a pH
of 7.7 ± 0.05. Therefore, the robustness of the method could
be concluded satisfactory.3.3. Applications to commercial tablets
Commercially available Norgesic and Myogesic tablets
were subjected to analysis using the proposed CE method.
The obtained RSD values for Norgesic and Myogesic tab-
lets were 1.88 and 1.70, respectively. The percentage of OC
per label for Norgesic tablets and Myogesic tablets was
107.14% and 99.38%, respectively. There is no monograph
for OC tablets in recent versions of BP (2007) or USP
(2008). However, there is a monograph for orphendrine
HCl tablets, with an assay limit of 92.5–107.5% (Righetti,
1996). Earlier versions of BP (1980) only contain a mono-
graph for OC slow release tablets, with an assay limit of
95–105% (United S, 2008). Referring to the monograph for
orphenadrine HCl tablets, both Norgesic and Myogesic
tablets could be concluded to be within pharmacopoeal
speciﬁcations.4. Conclusions
A selective, linear, precise, accurate method using CE was suc-
cessfully developed for the determination of OC in its tablet
formulations; alone or in the presence of PCTM. The method
employs a running buffer of 30 mM pentane sulfonate Na, dis-
solved in 20 mM MOPS buffer pH 7.7. When applied to com-
mercial tablets available in Jordanian market (Norgesic and
Myogesic) they were found within pharmacopoeal
speciﬁcations.References
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